# US 2020/0138926 A1 · Immunity-inducing agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138926 A1
- Document ID: US20200138926A1
- Status: Published application
- Kind: A1
- Application number: 16/746,204
- Filed: 2020-01-17
- Published: 2020-05-07
- Earliest claimed: 2015-04-30
- Assignees: Toray Industries, Inc.
- Applicants: Toray Industries, Inc.
- Inventors: Akira KURIHARA; Fumiyoshi OKANO
- Web page: https://patentgrep.com/patent/US20200138926A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 39/001174: {Proteoglycans, e.g. glypican, brevican or CSPG4}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/572: {cytotoxic response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.

## Claims

### Claim 1

A method of inducing immunity to a subject in need thereof, said method comprising administering an effective amount of an immunity-inducing agent to said subject;
wherein said immunity-inducing agent comprises, as an active ingredient, (i) at least one polypeptide having immunity-inducing activity and selected from the following polypeptides (a), (b), and (c), or (ii) a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing said polypeptide in vivo:
(a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14, and a polypeptide consisting of 7 or more consecutive amino acids in the amino acid sequence;
(b) a polypeptide having a sequence identity of 85% or more with the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14, and a polypeptide consisting of 7 or more consecutive amino acids in the amino acid sequence of the polypeptide; and
(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence.

### Claim 2 (depends on 1)

The method of inducing immunity according to claim 1, wherein the polypeptide having immunity-inducing activity is a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14.

### Claim 3 (depends on 1)

The method of inducing immunity according to claim 1, further comprising administering an immunoenhancer to said subject.

### Claim 4 (depends on 3)

The method of inducing immunity according to claim 3, wherein the immunoenhancer is at least one selected from the group consisting of a Freund's incomplete adjuvant, Montanide, Poly IC and derivatives thereof, CpG oligonucleotides, interleukin 12, interleukin 18, interferon α, interferon β, interferon ω, interferon γ, and a Flt 3 ligand.

### Claim 5

A method of treating cancer, said method comprising administering a pharmaceutical composition comprising an immunity-inducing agent and a pharmaceutically acceptable carrier to a subject in need thereof;
wherein said immunity-inducing agent comprises, as an active ingredient, (i) at least one polypeptide having immunity-inducing activity and selected from the following polypeptides (a), (b), and (c), or (ii) a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing said polypeptide in vivo:
(a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14, and a polypeptide consisting of 7 or more consecutive amino acids in the amino acid sequence;
(b) a polypeptide having a sequence identity of 85% or more with the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14, and a polypeptide consisting of 7 or more consecutive amino acids in the amino acid sequence of the polypeptide;
(c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence.

### Claim 6 (depends on 5)

The method of treatment according to claim 5, wherein the polypeptide having immunity-inducing activity is a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14.

### Claim 7 (depends on 5)

The method of treatment according to claim 5, wherein the cancer is a CSPG5 expressing cancer.

### Claim 8 (depends on 5)

The method of treatment according to claim 5, wherein the cancer is brain tumor, leukemia, malignant lymphoma, or neuroblastoma.

### Claim 9 (depends on 5)

The method of treatment according to claim 5, wherein said pharmaceutical composition comprises an immunoenhancer.

### Claim 10 (depends on 9)

The method of treatment according to claim 9, wherein the immunoenhancer is at least one selected from the group consisting of a Freund's incomplete adjuvant, Montanide, Poly IC and derivatives thereof, CpG oligonucleotides, interleukin 12, interleukin 18, interferon α, interferon β, interferon ω, interferon γ, and a Flt 3 ligand.
